Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00763360 · ClinicalTrials.gov registry record · Phase 4
To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.
A Phase 4 study of Cataract, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 184
- Enrollment target
- 1
- Study location
NCT00763360 is a Phase 4 study of Cataract that has completed, run by Alcon Research. The registered enrollment target is 184 participants, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00763360, a Phase 4 study of Cataract, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 184 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to assess how DisCoVisc Ophthalmic Viscosurgical Device (OVD) compares with Healon and Amvisc Plus in the protection of corneal endothelial cells, and the ability to maintain anterior chamber space, in routine cataract surgery.
Conditions Studied
Interventions
- DEVICE DisCoVisc®
- DRUG Healon
- DRUG Amvisc Plus
Study Locations (1)
Texas
- Alcon Call Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2008-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00763360
The ClinicalTrials.gov registry entry for NCT00763360 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 83 other Cataract trials with a reported enrollment target (19% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 3 interventions - of which DisCoVisc® is the first listed.
NCT00763360 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00763360 about?
NCT00763360 is a clinical study titled "To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.". The objective of the study is to assess how DisCoVisc Ophthalmic Viscosurgical Device (OVD) compares with Healon and Amvisc Plus in the protection of corneal endothelial cells, and the ability to maintain anterior chamber space, in routine cataract surgery.
What is the current status of trial NCT00763360?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 184 participants. The study started on 2008-05.
What conditions does trial NCT00763360 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT00763360?
The interventions under investigation include: DisCoVisc® (DEVICE), Healon (DRUG), Amvisc Plus (DRUG).
Who is sponsoring clinical trial NCT00763360?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00763360 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
RECRUITING · Phase 4
-
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
RECRUITING · Phase 4
-
Evaluation of a Monofocal Intraocular Lens
RECRUITING · Phase 4
-
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
RECRUITING · Phase 4
-
Odyssey Evaluation in Post LASIK Patients
RECRUITING · Phase 4
-
Dropless vs. Standard Drops Contralateral Eye Study
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.